Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

HIV R4P: Injectable Cabotegravir Makes Progress, Doubts About Injectable Rilpivirine

Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK1256744) that will be taken into efficacy trials to see if it can be used for pre-exposure prophylaxis (PrEP). Progress on an injectable formulation of another drug, rilpivirine, received a setback, however, when animal studies showed it lost its efficacy against viral challenge after only 18-21 days, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.

alt

Read more:

HIV R4P: Model Suggests More Frequent Truvada PrEP Needed for Vaginal vs Anal Sex

Tenofovir reaches lower levels in vaginal and cervical tissue compared with rectal tissue, helping to explain why pre-exposure prophylaxis (PrEP) did not protect women as much as gay and bisexual men in clinical trials, and suggesting that women having vaginal sex may need to take PrEP more often than people having anal sex, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.

alt

Read more:

HIV Research for Prevention Conference Features Advances in Vaccines, Microbicides, PrEP

The first HIV Research for Prevention -- or HIV R4P -- conference takes place this week in Cape Town, bringing together more than 1300 leading researchers, policymakers, and advocates working on interventions such as HIV vaccines, microbicides, antiretroviral treatment as prevention (TasP), and new forms of pre-exposure prophylaxis (PrEP). The conference incorporates the previously separate HIV vaccine and microbicide meetings as biomedical prevention technologies have converged.

alt

Read more:

Second European PrEP Study Closed Early Due to High Effectiveness

In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomized phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. All participants assigned to receive placebo in the IPERGAY trial will be offered intermittent Truvada PrEP.

alt

Read more:

High Effectiveness Seen in English PrEP Trial, All Will Be Offered Truvada

An interim analysis of the English PROUD study data has shown that daily Truvada pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay men and other men who have sex with men (MSM) at high risk of infection. On this basis, the PROUD Trial Steering Committee has announced that participants currently on the deferred arm of the study will be offered the opportunity to begin PrEP ahead of schedule.

alt

Read more: